



Jpw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**U.S. Serial No.:** 10/735,345

**Confirmation No. 6824**

**Applicants:** Economides et al.

**Filed:** 12 Dec 2003

**Group Art Unit:** 1646

**Examiner:** Kemmerer, Elizabeth

**Docket No.:** 132C

**Customer No.:** 26693

**FIRST CLASS MAIL CERTIFICATE**

I hereby certify that this paper is being deposited on this date with the U. S. Postal Service as first class mail addressed to the Commissioner of Patents and Trademarks, P.O. Box 1450, Alexandria, VA 22313-1450.

My: J. J. J.  
name

8/25/06  
Date

Commissioner for Patents  
U.S. Patent and Trademark Office  
P. O. Box 1450  
Alexandria, VA 22313-1450

**RESPONSE TO RESTRICTION DATED 2 AUGUST 2006**

Sir:

This paper is submitted in response to the Restriction action issued 2 August 2006 in the above-referenced case. Please amend the application as follows:

**Amendments to the Claims** are shown in the listing of claims beginning on page 2; and

**Remarks/Arguments** begin on page 4 of this paper.

Amendments to the claims:

Please cancel claims 3-5, 12-15, and 17-19 without prejudice to their renewal in a related patent application.

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (currently amended) A method of treating a bone morphogenetic protein (BMP)-related disorder or condition, comprising administering a BMP antagonist to a subject suffering from a BMP-related disorder or condition, wherein the BMP-related disorder or condition is treated, wherein the BMP antagonist is human noggin (hNOG) (SEQ ID NO:2), a noggin variant, or a fragment thereof capable of acting as a BMP antagonist.

2. (original) The method of claim 1, wherein the BMP-related disorder or condition is heterotopic cranial synostosis, fibrodysplasia ossificans progressiva (FOP), or sclerostosis.

3-5. (canceled)

6. (currently amended) The method of claim 5~~1~~, wherein the hNOG variant is a deletion mutant hNOG $\Delta$ B2 (SEQ ID NO:10).

7-9. (canceled)

10. (currently amended) A method of blocking biological activity of a bone morphogenetic protein (BMP) in a subject, comprising administering an agent capable of blocking BMP biological activity, wherein the BMP antagonist is human noggin (hNOG) (SEQ ID NO:2), a noggin variant, or a fragment thereof capable of acting as a BMP antagonist.

11. (original) The method of claim 10, wherein the BMP-related disorder or condition is carnosynostosis or fibrodysplasia ossificans progressiva (FOP).

12-15. (canceled)

16. (currently amended) The method of claim ~~15~~ 12, wherein the hNOG variant is hNOG $\Delta$ B2 (SEQ ID NO:10).

17-19. (canceled)

20. (currently amended) A method of inhibiting the progress of a bone morphogenetic protein (BMP)-related disorder or condition, comprising administering ~~the pharmaceutical composition of claim 19~~ human noggin (hNOG) (SEQ ID NO:2) or hNOG $\Delta$ B2 (SEQ ID NO:10) to a subject suffering from a BMP-related disorder or condition, wherein the BMP-related disorder or condition is treated.